NMS Labs and PinneyAssociates Announce Collaborative Agreement to Provide In Vitro Abuse-Deterrent Assessment Services
WILLOW GROVE, Pa. and BETHESDA, Md., Jan. 16, 2019 /PRNewswire/ -- NMS Labs and PinneyAssociates have established a collaborative agreement to provide comprehensive guidance on and implementation of in vitro assessment of abuse-deterrent drugs and formulations for pharmaceutical companies developing drugs that act on the central nervous system.
Founded in 1994, PinneyAssociates provides comprehensive expert guidance on the in vitro assessment of abuse-deterrent drugs and formulations and interpretation of the resulting data.
Established in 1972, NMS Labs is a full-service laboratory with more than 15 years' experience in the development and performance of in vitro abuse-deterrent testing.
PinneyAssociates' scientists include internationally respected leaders in the evolving science of in vitro laboratory assessments, sometimes called tamper testing, of abuse-deterrent drugs and formulations, including the design and development of protocols. Through their interactions with the Food and Drug Administration (FDA), PinneyAssociates' experts have unique insights into regulators' expectations related to abuse-deterrent evaluations. Through collaborations with other service providers, the company offers comprehensive assessment of abuse-deterrent drugs and formulations, as well as animal and human abuse potential assessment related services.
NMS Labs is a state-of-the-art toxicology and clinical testing facility which has been a pioneer and leader in abuse deterrence and tamper-resistant testing since 2002, developing innovative practices for testing abuse-deterrent formulations for opioids and other substances of abuse. The Labs' testing processes have been widely recognized and accepted by government regulatory bodies since the emergence of the opioid crisis.
Together, NMS Labs and PinneyAssociates will deliver comprehensive, world-class service in the area of in vitro laboratory testing of abuse-deterrent drugs and product formulations for submission to FDA.
For more information on NMS Labs, please visit www.nmslabs.com.
For more information on PinneyAssociates, please visit www.pinneyassociates.com
For more information, contact:
NMS Labs
Ike Harper, Business Development Pharmaceutical Services, ike.harper@nmslabs.com, (215) 366-1395
PinneyAssociates
Michelle Ertischek, mertischek@pinneyassociates.com, (240) 752-9053
SOURCE PinneyAssociates; NMS Labs
Share this article